Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0917816 (
mental retardation
)
15,867
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We detected morphologic abnormalities in the cerebral cortex of Mecp2-hemizygous (Mecp2(-/y)) mice. The cortical thickness of both somatosensory and motor cortices in mutants did not increase after 4 weeks of age, as compared with that in wild-type male mice. The density of neurons in those areas was significantly higher in layers II/III and V of Mecp2(-/y) mice than in wild-type mice, particularly in layers II/ III after 4 weeks of age. In layer II/III of the somatosensory cortex of Mecp2(-/y) mice, the diameter of the apical dendrite was thin and the number of dendritic spines was small. Electron microscopy revealed that two-week-old mutants already had numerous premature postsynaptic densities. These results indicate that Mecp2(-/y) mice suffered delayed neuronal maturation of the cerebral cortex and that the initial neuronal changes were caused by premature synaptogenesis.
Rett syndrome
patients with a heterozygous mutation of Mecp2 display developmental disorders including cortical malfunctions such as
mental retardation
, autism, and epilepsy. Our results provide evidence of the similarity with
Rett syndrome
brains in some respects and suggest that
MeCP2
/Mecp2 plays some role in synaptogenesis.
...
PMID:Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. 1597 46
Rett syndrome
(
RTT
) is a severe form of
mental retardation
, which is caused by spontaneous mutations in the X-linked gene MECP2. How the loss of
MeCP2
function leads to
RTT
is currently unknown. Mice lacking the Mecp2 gene initially show normal postnatal development but later acquire neurological phenotypes, including heightened anxiety, that resemble
RTT
. The MECP2 gene encodes a
methyl-CpG-binding protein
that can act as a transcriptional repressor. Using cDNA microarrays, we found that Mecp2-null animals differentially express several genes that are induced during the stress response by glucocorticoids. Increased levels of mRNAs for serum glucocorticoid-inducible kinase 1 (Sgk) and FK506-binding protein 51 (Fkbp5) were observed before and after onset of neurological symptoms, but plasma glucocorticoid was not significantly elevated in Mecp2-null mice.
MeCP2
is bound to the Fkbp5 and Sgk genes in brain and may function as a modulator of glucocorticoid-inducible gene expression. Given the known deleterious effect of glucocorticoid exposure on brain development, our data raise the possibility that disruption of
MeCP2
-dependent regulation of stress-responsive genes contributes to the symptoms of
RTT
.
...
PMID:Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. 1600 17
Loss-of-function mutations of the MECP2 gene at Xq28 are associated with
Rett syndrome
in females and with syndromic and nonsyndromic forms of
mental retardation
(MR) in males. By array comparative genomic hybridization (array-CGH), we identified a small duplication at Xq28 in a large family with a severe form of MR associated with progressive spasticity. Screening by real-time quantitation of 17 additional patients with MR who have similar phenotypes revealed three more duplications. The duplications in the four patients vary in size from 0.4 to 0.8 Mb and harbor several genes, which, for each duplication, include the MR-related L1CAM and MECP2 genes. The proximal breakpoints are located within a 250-kb region centromeric of L1CAM, whereas the distal breakpoints are located in a 300-kb interval telomeric of MECP2. The precise size and location of each duplication is different in the four patients. The duplications segregate with the disease in the families, and asymptomatic carrier females show complete skewing of X inactivation. Comparison of the clinical features in these patients and in a previously reported patient enables refinement of the genotype-phenotype correlation and strongly suggests that increased dosage of MECP2 results in the MR phenotype. Our findings demonstrate that, in humans, not only impaired or abolished gene function but also increased
MeCP2
dosage causes a distinct phenotype. Moreover, duplication of the MECP2 region occurs frequently in male patients with a severe form of MR, which justifies quantitative screening of MECP2 in this group of patients.
...
PMID:Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. 1608 Jan 19
About 80% of female patients with
Rett syndrome
(
RTT
) display a mutation in the
methyl-CpG-binding protein 2
(
MECP2
) gene, but most males with
MECP2
mutation experience severe fatal encephalopathy or non-specific X-linked
mental retardation
(XLMR). The existence of male
RTT
has been extensively discussed. We report herein a boy with classic
RTT
in a family with a missense mutation in
MECP2
. The mother exhibited slight
mental retardation
and was a carrier for R133C. The patient could stand with support at 12-months-old, and stereotypic hand movements appeared at 3-years-old. He became bed-ridden by 8-years-old. The R133C mutation was present in
MECP2
without somatic mosaicism. A sister with R133C displayed classic
RTT
. The R133C mutation has been detected in female patients with classic and preserved speech variant
RTT
, but not in males with non-specific XLMR. These results suggest that clinical phenotypes caused by DNA mutation in
MECP2
are determined by position of the mutation in the gene, and R133 represents a critical amino acid residue in the induction of
RTT
symptoms in humans.
...
PMID:Classic Rett syndrome in a boy with R133C mutation of MECP2. 1612 33
Autism is a heterogeneous neurodevelopmental disorder with a 3-4 times higher sex ratio in males than females. X chromosome genes may contribute to this higher sex ratio through unusual skewing of X chromosome inactivation. We studied X chromosome skewness in 30 females with classical autism and 35 similarly aged unaffected female siblings as controls using the polymorphic androgen receptor (AR) gene. Significantly, increased X chromosome skewness (e.g., >80:20%) was detected in our autism group (33%) compared to unaffected females (11%). X chromosome skewness was also seen in 50% of the mothers with autistic daughters. No mutation was seen in the promoter region of the XIST gene reported to be involved in X chromosome inactivation in our subjects. X chromosome skewness has been reported in female carriers of other neurological disorders such as X-linked
mental retardation
, adrenoleukodystrophy and
Rett syndrome
.
...
PMID:Brief report: non-random X chromosome inactivation in females with autism. 1616 93
Rett syndrome
is a neurodevelopmental disorder that primarily affects girls, most of whom have mutations in the transcription regulatory gene MECP2. However, mutations in MECP2 also have been identified in normal carrier female individuals, female individuals with mild learning disabilities and features of Angelman syndrome, and male individuals with Klinefelter syndrome or
Rett syndrome
-like features, fatal neonatal encephalopathy, and familial X-linked
mental retardation
with or without motor abnormalities. Therefore, molecular testing should be considered for a wide spectrum of individuals. As such,
Rett syndrome
remains a clinical diagnosis. In this article, we also discuss three recent developments: (1) the recognition of significant gallbladder dysfunction, especially in those 20 years of age or younger; (2) a clinical trial of folate and betaine, which produced no objective improvement but did yield a subjective increase in attention and interaction; and (3) measurement of cerebrospinal fluid folate levels in a large cohort, which yielded normal values, indicating no need for supplementation.
...
PMID:Rett syndrome: model of neurodevelopmental disorders. 1622 24
Rett syndrome
is a leading cause of postnatal neurodevelopmental regression.
Rett syndrome
is caused by mutations in MECP2, the gene encoding methyl-CpG binding protein 2. In up to 96% of all classic cases,
Rett syndrome
cases are caused by mutations or deletions in MECP2. The phenotypic spectrum of MECP2 mutations is broad and includes
mental retardation
with or without seizures, Angelman syndrome-like phenotype, and autism. Mecp308/Y mice carry a truncating mutation and display many of the features seen in
Rett syndrome
. Social behavior abnormalities and impaired social interactions in Mecp308/Y mice suggest that
MeCP2
plays a role in modulating the activity of genes and neurons important for social interactions. Mice that overexpress
MeCP2
at twice the endogenous levels develop a progressive neurologic disorder, demonstrating that
MeCP2
levels are tightly regulated and raising the possibility that duplications or gain-of-function mutations of MECP2 might underlie some cases of neurodevelopmental X-linked disorders.
...
PMID:MeCP2 dysfunction in humans and mice. 1622 28
Rett syndrome
is a neurodevelopmental disorder and an important cause of
mental retardation
and autistic behavior in girls and in a small group of boys. In 1999, mutation of the methyl-CpG binding protein 2 (MECP2) gene encoding a transcriptional repressor on the X chromosome was found to cause
Rett syndrome
. Since this discovery, significant research has focused on the elucidation of its specific role in the central nervous system. Recent studies revealed that MECP2 is expressed in more differentiated neurons rather than in less differentiated neuroblasts and that MECP2 is involved in the maturation and maintenance of neurons, including dendritic arborization and axonal projections, rather than in early cell fate decisions in the mammalian brain. In this review, we summarize recent findings regarding regional, temporal, and cell type-specific MECP2 expression in the central nervous system; neurobiologic abnormalities in MECP2 -mutant mice; and MECP2 target genes in the central nervous system.
...
PMID:Dissecting MECP2 function in the central nervous system. 1622 31
Positron emission tomography (PET) is a technique that enables imaging of the distribution of radiolabeled tracers designed to track biochemical and molecular processes in the body after intravenous injection or inhalation. New strategies for the use of radiolabeled tracers hold potential for imaging gene expression in the brain during development and following interventions. In addition, PET may be key in identifying the physiological consequences of gene mutations associated with
mental retardation
. The development of high spatial resolution microPET scanners for imaging of rodents provides a means for longitudinal study of transgenic mouse models of genetic disorders associated with
mental retardation
. In this review, we describe PET methodology, illustrate how PET can be used to delineate biochemical changes during brain development, and provide examples of how PET has been applied to study brain glucose metabolism in
Rett syndrome
, serotonin synthesis in autism, and GABAA receptors in Angelman's syndrome and Prader-Willi syndrome. Future application of PET scanning in the study of
mental retardation
might include measurements of brain protein synthesis in fragile X syndrome and tuberous sclerosis complex, two common conditions associated with
mental retardation
in which cellular mechanisms involve dysregulation of protein synthesis. Mental retardation results in life-long disability, and application of new PET technologies holds promise for a better understanding of the biological underpinnings of
mental retardation
, with the potential to uncover new treatment options.
...
PMID:Positron emission tomography methods with potential for increased understanding of mental retardation and developmental disabilities. 1624 Apr 13
Rett syndrome
(
RTT
) is a postnatal neurodevelopmental disorder characterized by the loss of acquired motor and language skills, autistic features, and unusual stereotyped movements.
RTT
is caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2). Mutations in MECP2 cause a variety of neurodevelopmental disorders including X-linked
mental retardation
, psychiatric disorders, and some cases of autism. Although MeCP2 was identified as a methylation-dependent transcriptional repressor, transcriptional profiling of RNAs from mice lacking MeCP2 did not reveal significant gene expression changes, suggesting that MeCP2 does not simply function as a global repressor. Changes in expression of a few genes have been observed, but these alterations do not explain the full spectrum of Rett-like phenotypes, raising the possibility that additional MeCP2 functions play a role in pathogenesis. In this study, we show that MeCP2 interacts with the RNA-binding protein Y box-binding protein 1 and regulates splicing of reporter minigenes. Importantly, we found aberrant alternative splicing patterns in a mouse model of
RTT
. Thus, we uncovered a previously uncharacterized function of MeCP2 that involves regulation of splicing, in addition to its role as a transcriptional repressor.
...
PMID:Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. 1625 Dec 72
<< Previous
1
2
3
4
5
6
7
8
9
10